Mon, Dec 22, 2014, 9:02 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Vanda Pharmaceuticals, Inc. Message Board

  • fossilmark fossilmark Jun 4, 2014 9:03 PM Flag

    220 prescriptions in first six weeks seems very strong . . . .

    In the last three years, revenue has been $31M, $33M, and $34M. Analyst consensus is $45M, implying about $10M expected from Hetlioz. At $84,000 per patient per year, that's 120 patient years of therapy or 240 patient half years of therapy. Of course there will be discounts, prescriptions that don't get filled due to lack of reimbursement, patients who drop off after one or two prescriptions etc. That said, 120 patient years of therapy is 1,440 filled prescriptions. 220 prescriptions in 6 weeks, 110 of which have been reimbursed and filled, when you need 1,440 filled prescriptions to meet analyst consensus seems, like a very strong start!

    Maybe that is why the stock is up 25% today.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
VNDA
11.91-0.34(-2.78%)Dec 22 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Gilead Sciences Inc.
NASDAQMon, Dec 22, 2014 4:00 PM EST
Henry Schein, Inc.
NASDAQMon, Dec 22, 2014 4:00 PM EST
Rite Aid Corporation
NYSEMon, Dec 22, 2014 4:01 PM EST